High variability in baseline urinary free cortisol values in patients with Cushing's disease by Petersenn, Stephan et al.
O R I G I N A L A R T I C L E
High variability in baseline urinary free cortisol values in patients
with Cushing’s disease
S. Petersenn*, J. Newell-Price†, J. W. Findling‡, F. Gu§, M. Maldonado¶, K. Sen**, L. R. Salgado††, A. Colao‡‡
and B. M. K. Biller§§ on behalf of the Pasireotide B2305 Study Group
*ENDOC Center for Endocrine Tumors, Hamburg, Germany, †The Medical School, University of Sheffield, Sheffield, UK, ‡Division
of Endocrinology, Metabolism, and Clinical Nutrition, Medical College of Wisconsin, Milwaukee, WI, USA, §Department of
Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Beijing, China,
¶Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland, **Oncology Biometrics and Data
Management, Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA, ††General Internal Medicine Service, Hospital das
Clınicas, University of S~ao Paulo Medical School, S~ao Paulo, Brazil, ‡‡Dipartimento di Medicina Clinica e Chirurgia, Sezione di
Endocrinologia, Universita di Napoli ‘Federico II’, Naples, Italy and §§Neuroendocrine Clinical Center, Massachusetts General
Hospital, Boston, MA, USA
Summary
Objective Twenty-four-hour urinary free cortisol (UFC) sam-
pling is commonly used to evaluate Cushing’s syndrome.
Because there are few data on UFC variability in patients with
active Cushing’s disease, we analysed baseline UFC in a large
patient cohort with moderate-to-severe Cushing’s disease and
assessed whether variability correlates with hypercortisolism
severity. These data will help clinicians establish the minimum
number of UFC samples required to obtain reliable data.
Design Observational study (enrolment phase of Phase III
study).
Methods Patients (n = 152) with persistent/recurrent or de
novo Cushing’s disease and mean UFC (mUFC) ≥159ULN
(normal: 30–145 nmol/24 h) were included. Mean UFC level
was calculated from four 24-h urine samples collected over
2 weeks.
Results Over 600 24-h UFC samples were analysed. The mUFC
levels of samples 1 and 2 and samples 3 and 4 were 1000 nmol/
24 h (SD 1872) and 940 nmol/24 h (SD 2148), respectively;
intrapatient coefficient of variation (CV) was 38% for mUFC.
The intrapatient CV using all four samples was 52% (95% CI:
48–56). The intrapatient CV was 51% (95% CI: 44–58) for sam-
ples 1 and 2, 49% (95% CI: 43–56) for samples 3 and 4 and
54% (95% CI: 49–59) for samples 1, 2 and 3. Variability in
mUFC increased as UFC levels increased. There were no correla-
tions between UFC and clinical features of hypercortisolism.
Conclusions There is intrapatient variability of approximately
50% in 24-h UFC measurements, which is relevant to targets set
to estimate any treatment effect. Analysing more than two 24-h
collection periods in individual patients does not result in a
relevant decrease in variability. Interestingly, UFC levels did not
correlate with hypercortisolism severity.
(Received 6 March 2013; returned for revision 25 March 2013;
finally revised 24 May 2013; accepted 1 June 2013)
Introduction
Cushing’s disease is caused by hypersecretion of adrenocortico-
trophic hormone (ACTH) from a corticotroph adenoma,1,2
which in turn causes overproduction of cortisol from the adre-
nal glands. Patients with Cushing’s disease have a 55-fold higher
mortality than the general population3 and tend to have numer-
ous comorbidities, including central obesity, osteoporosis,
systemic arterial hypertension, insulin resistance, glucose intoler-
ance, diabetes mellitus, dyslipidaemia and cardiovascular dis-
ease.4,5 Early diagnosis and treatment of chronic hypercortisolism
are paramount, because a long duration of disease is associated
with increasingly severe complications. Effective treatment
improves life expectancy in patients with Cushing’s disease.6,7
The evaluation of a patient with suspected hypercortisolism is
often complex and expensive.8 The pulsatile nature and circadian
variability of ACTH and cortisol secretion in healthy individuals
and in patients with Cushing’s syndrome mean that random
blood ACTH and cortisol sampling are not useful for diagnosis
(or for evaluating a patient during treatment). The Endocrine
Society recommends measurement of 24-h urinary free cortisol
(UFC), late-night salivary cortisol, or cortisol suppression during
a 1-mg overnight dexamethasone suppression test (DST), or
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48-h low-dose DST, for the detection of Cushing’s syndrome.9 A
systematic review and meta-analysis of the literature on diagnos-
tic tests for Cushing’s syndrome showed that UFC and overnight
DST have the most evidence to support their use, although the
receiver operator characteristic curves for UFC were slightly infe-
rior to those for DST.10
Despite shortcomings, UFC measurements are often used in
medical practice to diagnose Cushing’s disease, to assess for
remission after pituitary surgery, to evaluate the efficacy of med-
ical treatments and to monitor for recurrence.8,11,12 The reliabil-
ity and reproducibility of this test are very important. The
Endocrine Society recommendations state that at least two 24-h
UFC measurements should be performed for the diagnosis of
Cushing’s syndrome.9 It is, however, currently unclear whether
two 24-h collections are sufficient to establish a reasonable esti-
mate of the secretory activity of the underlying pituitary
adenoma or whether more than two measurements are required.
In addition, the level of intra-individual variability when using
this test is not known.
The aim of this study was to use the four baseline UFC
measurements taken from each patient in the randomized, dou-
ble-blind, Phase III study of pasireotide (NCT00434148)13 to
quantify the intrapatient variability of UFC levels in patients
with Cushing’s disease. In addition, the study aimed to show
whether a greater number of UFC measurements leads to greater
accuracy of UFC measurement and more precise estimation of
intrapatient variation and whether UFC levels correlate with the
severity of clinical features of hypercortisolism.
Methods
Patients and study design
Men and women aged ≥18 years with persistent/recurrent or de
novo (if not surgical candidates) Cushing’s disease were eligible
for enrolment into this international, multicentre study.13
Patients had a confirmed diagnosis of Cushing’s disease defined
as: a mean UFC (mUFC) level at least 15 times the upper limit
of the normal range (ULN) calculated from four 24-h urine
samples collected within 2 weeks; morning plasma ACTH within
the normal range or above the ULN; and either magnetic reso-
nance imaging confirmation of a pituitary macroadenoma
(≥10 mm), inferior petrosal sinus sampling (IPSS) gradient >3
after corticotrophin-releasing hormone (CRH) stimulation for
patients with a microadenoma (<10 mm) or histopathology
confirming an ACTH-staining adenoma.14 If IPSS had previously
been performed without CRH (e.g. with desmopressin),15 then a
central to peripheral prestimulation gradient >2 was required. If
IPSS had not previously been performed, IPSS with CRH stimu-
lation was required. Only patients with four baseline UFC
samples were included in the present analysis.
Patients were excluded from the clinical trial if they had
received pituitary irradiation within the last 10 years (patients
were eligible if they had been treated more than 10 years before
enrolment), had been treated with mitotane during the
6 months prior to visit 1 or had optic chiasm compression caus-
ing any visual field defect or Cushing’s syndrome due to nonpi-
tuitary sources or an inherited syndrome. In patients who had
received previous medical treatment for Cushing’s disease, the
following washout periods were employed before baseline UFC
was assessed: 1 week for steroidogenesis inhibitors (ketoconaz-
ole, metyrapone), octreotide sc and rosiglitazone; 4 weeks for
dopamine agonists (bromocriptine, cabergoline) and lanreotide
SR; and 8 weeks for octreotide LAR and lanreotide Autogel.
This Phase III study was approved by the independent ethics
committee, research ethics board or institutional review board at
each centre and complied with the ICH Harmonised Tripartite
Guidelines for Good Clinical Practice, the Declaration of
Helsinki and local laws. All patients provided written informed
consent.
UFC measurements and other assays
At baseline (visit 1), four 24-h urine samples were collected over
a 2-week period and were used to calculate the mUFC level for
each patient; each collection took place from 0800 h to 0800 h
the following day. Patients were given both written and verbal
instructions for collecting and storing the urine samples. The
first morning urine was not collected on day 1, but was included
on the second day, ending the 24-h collection period. Urinary
analyses took place at central laboratories, and the volume for
each collection was noted. UFC was measured in duplicate by
high-performance liquid chromatography (HPLC) as described
previously,16 using the Alliance 2795 High Throughput System
(Waters Corp, Milford, MA, USA). The normal range for this
assay is 30–145 nmol/24 h (approximately 11–53 lg/24 h),
which was determined based on an analysis of 24-h urine sam-
ples from 28 healthy individuals.16 The intra-assay variability
was 61% at a concentration of 5 nmol/l, 55% at 15 nmol/l,
15% at 75 nmol/l, 37% at 400 nmol/l and 09% at 2000 nmol/l.
The interassay precision was 57% at 15 nmol/l, 24% at
75 nmol/l, 24% at 400 nmol/l and 46% at 2000 nmol/l. The
interassay precision was not calculated at 5 nmol/l. The total
accuracy was 100  15%. All samples were analysed by central
laboratories [Eurofins Medinet BV, Breda, The Netherlands, for
Europe; CRL Medinet Inc, Lenexa, KS, USA, for North/South
America; and Eurofins Technology Services (Suzhou) Co Ltd,
Suzhou, China, for China]. All three laboratories were consistent
in the procedures used.
Height, weight, blood pressure, fasting glucose, insulin,
glycosylated haemoglobin (HbA1C) and creatinine levels were
also collected. Body mass index (BMI), insulin resistance
[homeostasis model assessment (HOMA) IR] and b-cell func-
tion (HOMA b) were calculated.
Statistical methods
The degree of UFC variability was determined from the four
urine samples collected from individual patients. The na€ıve esti-
mator of the true intrapatient coefficient of variation (CV)
obtained as the average of the intrapatient CV for individual
patients has been found to underestimate the true intrapatient
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CV.17 Therefore, a logarithmic transformation was applied to
the UFC values before estimating the intrapatient variability
using a variance components model. Intrapatient CV was calcu-
lated as follows: intrapatient CV = antilog [intrapatient standard
deviation (SD) on the log scale] 1. The effect of baseline UFC
levels (i.e. ≤2 vs >29ULN and ≤5 vs >59ULN) and disease
status (i.e. de novo vs recurrent/persistent) on intrapatient UFC
variability was evaluated by estimating the CV (as described
above) for these subgroups. Analyses regarding the effect of mul-
tiple UFC samples (four vs three vs two) on intrapatient UFC
variability were also performed.
The impact of averaging multiple UFC samples on the preci-
sion of the UFC assessment was evaluated by deriving the intra-
patient CV corresponding to the average of two, three and four
samples. For this derivation, the intrapatient SD obtained by the
method described above is divided by the square root of the
number of UFC samples to arrive at the intrapatient SD of an
average of multiple UFC samples. For the two-sample case, the
intrapatient CV was also empirically determined by averaging
samples 1 and 2 separately from samples 3 and 4 for all patients
with four samples. The 975% lower confidence bound of the
relative difference between two baseline UFC assessments of the
same patient was computed to determine a threshold beyond
which an intervention effect could be considered highly unlikely
to be due to random UFC variation. The computations were
performed for the average of two, three and four samples,
assuming log-normal distribution of the UFC values.
A linear correlation analysis between baseline UFC and base-
line fasting glucose, HbA1C, fasting insulin, fasting HOMA IR,
HOMA b, BMI and sitting systolic and diastolic blood pressure
was performed to assess the relationship between UFC level and
the severity of clinical features of Cushing’s disease. Pearson
correlation coefficients are reported.
Results
Baseline demographics and characteristics
Of the 162 patients who entered the study, 152 (938%) had
four UFC measurements at baseline. The baseline demographic
and disease characteristics of these 152 patients are presented in
Table 1.
Most patients had persistent/recurrent Cushing’s disease and
had undergone surgical intervention but not pituitary irradia-
tion. Almost all patients (98%) reported at least one continuing
medical condition at baseline. The most frequently reported
comorbidities were hypertension (780% of patients), osteoporo-
sis (228%), diabetes mellitus (339%), hypothyroidism (204%),
hypercholesterolaemia (180%), hyperlipidaemia (167%) and
depression (160%).
As shown in Table 2, mean baseline UFC was 972 
1985 nmol/24 h (352  720 lg/24 h). Most patients had mod-
erate-to-severe hypercortisolism (>29ULN; Fig. 1), and almost
50% of patients had a mUFC level ≥49ULN. It should be noted
that prior to a protocol amendment, UFC was assessed at
screening (two samples) and again at baseline (study day 1; four
samples); one patient included in this analysis was enrolled
before the amendment and had an eligible mUFC level at
screening but an mUFC level that was <159ULN when assessed
at baseline.
Table 1. Demographic and disease characteristics
Characteristics
All patients with four baseline UFC
measurements (N = 152)
Age, years
Mean  SD 403  119
≥65, n (%) 5 (33)
Sex, n (%)
Female 120 (789)
Race, n (%)
Caucasian 119 (783)
Black 2 (13)
Asian 20 (132)
Native American 4 (26)
Other 6 (39)
Missing 1 (07)
Time since diagnosis, months
Mean  SD 532  630
Median (range) 297 (01–3721)
Cushing’s disease status, n (%)
De novo 25 (164)
Persistent/recurrent 127 (836)
Previous surgery, n (%) 121 (796)
Previous pituitary irradiation,
n (%)
7 (46)*
Previous medication for
Cushing’s disease, n (%)
71 (467)
SD, standard deviation; *Two of the seven patients received pituitary
irradiation within 10 years prior to study entry.
Table 2. Baseline UFC, creatinine levels and urinary volumes
Characteristics Patients (N = 152)
Baseline mUFC (mean of four UFC samples)
Mean  SD, nmol/24 h 972  1985
Mean  SD, lg/24 h 352  720
Median (range), nmol/24 h 561 (195–22 944)
Median (range), lg/24 h 203 (71–8316)
Baseline urinary creatinine
Mean  SD, nmol/24 h 95  31
Mean  SD, mg/24 h 1076  354
Mean baseline urinary volume  SD, ml/24 h 2121  909
Hypercortisolism severity, n (%)
Mild (mUFC ≤29ULN) 26 (171)
Moderate (mUFC >2–59ULN) 66 (434)
Severe (mUFC >5–109ULN) 40 (263)
Very severe (mUFC >109ULN) 20 (132)
mUFC, mean urinary free cortisol in an individual patient; SD, standard
deviation; ULN, upper limit of normal (145 nmol/24 h; 53 lg/24 h).
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Baseline UFC variability
The individual baseline UFC levels exhibited non-normal distri-
bution, due to the mean cortisol threshold of ≥159ULN
required for inclusion into the study. Seven patients had one or
more individual UFC values in the normal range, despite the
mean of their four UFC values being ≥159ULN. Four of these
patients had one value in the normal range, and three patients
had two normal values. As shown in Fig. 2, for the group as
a whole, the mean and median UFC levels from UFC samples
1 and 2 were similar to those collected from samples 3 and
4. However, the intrapatient CV between the mean of samples
1 and 2 and the mean of samples 3 and 4 was 38%.
When individual patient data were examined, the variability in
UFC levels increased as UFC levels increased (Fig. 3a). This was
supported by the analysis of variability according to baseline UFC
category (calculated using all four samples), where patients with
UFC ≤29ULN had an intrapatient CV of 35% [95% confidence
interval (CI): 29–42; n = 26] compared with 55% (95% CI: 50–60;
n = 126) in those with UFC >29ULN. Similarly, patients with UFC
≤59ULN had an intrapatient CV of 45% (95% CI: 41–50; n = 92)
compared with 62% (95% CI: 54–71; n = 60) in those with UFC
>59ULN. There was a correlation between the first two baseline
UFC samples from the same patient (Fig. 3b). No apparent trend
over time was evident in the variability from the first to the last
sample (Fig. 3c). The widest intrapatient range was 600–14 020
nmol/24 h (2175–50815 lg/24 h). In the 25 patients with de novo
Cushing’s disease, the intrapatient CV (calculated using all four
samples) was 38% (95% CI: 31–46) compared with 55% (95% CI:
50–60) in the 127 patients with persistent/recurrent disease.
The overall intrapatient CV calculated using all four baseline
UFC samples was 52% (95% CI: 48–56). The intrapatient CVs
calculated using two or three UFC measures were similar but
had slightly wider CIs. The intrapatient CV was 51% (95% CI:
44–58) when samples 1 and 2 were used, 49% (95% CI: 43–56)
when samples 3 and 4 were used and 54% (95% CI: 49–59)
when samples 1, 2 and 3 were used.
The intrapatient CV of baseline UFC assessments is high; there-
fore, it is desirable to average at least two UFC samples to accu-
rately estimate a patient’s baseline UFC level. While averaging two
UFC samples is expected to reduce the CV to 346% (consistent
with the 38% reported earlier as the intrapatient CV for the mean
of samples 1 and 2 and the mean of samples 3 and 4), averaging
three and four UFC samples is expected to reduce the CV further
to 275% and 234%, respectively. An intrapatient CV of 346%
implies that there is a 975% chance that one baseline UFC mea-
surement could be lower than another baseline measurement of
the same patient by at most 56%. In other words, the reduction in
UFC from baseline would have to be greater than 56% to be con-
sidered highly unlikely to be due to random variation in UFC lev-
els. Similarly, an intrapatient CV of 275% (when averaging three
UFC samples) and 234% (when averaging four UFC samples)
implies that the reduction in UFC from baseline would have to be
greater than 49% and 44%, respectively, to be considered highly
unlikely to be due to random variation in UFC levels.
Correlation of baseline mUFC with clinical features of
Cushing’s disease
There was no linear correlation between baseline mUFC and
fasting glucose, HbA1C, fasting insulin, insulin resistance, b-cell
function, BMI or systolic/diastolic blood pressure (Fig. 4).
Fig. 1 Distribution of baseline mean urinary free cortisol (UFC) values
expressed as a percentage of the upper limit of normal (ULN), calculated
from the mean of four UFC values for each patient.
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Discussion
This study shows that in patients with moderate-to-severe hyper-
cortisolism, the intrapatient CV across two or more UFC samples
is approximately 50% and that variability increases with progres-
sively higher UFC levels. This is important because it is clinically
valuable for physicians to be aware that there can be a high degree
of variability in UFC levels in any individual patient. Interestingly,
patients with de novo Cushing’s disease had lower variability in
baseline UFC than those with persistent/recurrent disease; the rea-
son for this difference is unclear. Patients with persistent/recurrent
disease may have a more aggressive form of tumour with a differ-
ent pattern of ACTH secretion compared with de novo patients. In
addition, it is possible that previous surgery has altered the struc-
ture of the underlying pituitary tumour, and any remnant/recur-
rence of this leads to a different ACTH secretion pattern. Several
extrinsic factors have been shown to modify the excretion of UFC,
including alcoholism,18 polycystic ovarian syndrome19 and an-
orexia nervosa.20 Patients with a recent history of alcohol abuse
were excluded from the study and there were no patients with a
history of anorexia, although eight female patients with active
polycystic ovarian syndrome were enrolled. The intrapatient CV
between the mean of UFC samples 1 and 2 and the mean of UFC
samples 3 and 4 was lower, but was still 38%. Overall, UFC was
lower in samples 3 and 4 than in samples 1 and 2, but this is unli-
kely to be a washout phenomenon because the UFC samples could
have been taken at any point within the 2-week period and there
was no clear trend for UFC levels to decrease throughout the 2-
week period. Although the reproducibility of late-night salivary
cortisol has been measured previously,21 to our knowledge, this is
the first such analysis of the intrapatient variance of 24-h UFC
measurements. This study is unique because it was conducted in a
large patient population that provided over 600 UFC samples for
evaluation. These analyses demonstrate the wide variations in
UFC measurements that occur over a short period of time within
individual patients and have important implications for the diag-
nosis of Cushing’s disease and the assessment of treatment effi-
cacy. These data imply that for a patient who has moderate-to-
severe Cushing’s disease, reductions in UFC from baseline (based
on the average of two UFC samples) should be greater than 56%
for an intervention effect to be considered beyond the normal var-
iability of UFC.
The data can also be used to evaluate how many UFC mea-
surements should be collected when evaluating Cushing’s
disease. In this study, a two-sample 24-h UFC measurement was
found to yield a reasonable estimate of intrapatient variation
(95% CI: 44–58%). Narrower CIs, and therefore more precise
estimates, were obtained when using three (95% CI: 49–59%) or
four (95% CI: 48–56%) UFC measurements. However, practical
considerations in clinical practice may prevent the routine col-
lection of four 24-h UFC samples, because patients may find the
task inconvenient. The results of this study therefore suggest that
in this range of cortisol excess, taking the mean of two samples
would provide sufficient information for use in everyday care.
No linear correlation was found in the present study between
mUFC levels and the severity of features of hypercortisolism,
including fasting glucose, HbA1C, fasting insulin, insulin resis-
tance, b-cell function, BMI or systolic/diastolic blood pressure.
This is perhaps surprising because it might be expected that higher
UFC levels would correlate with disease severity and therefore with
morbidity levels. Previous studies have shown that higher UFC
levels in patients with Cushing’s disease are associated with more
severe cognitive impairment,22 the presence of major depression23
and the risk of serious infection.24,25 It is, however, possible that
disease severity is associated with duration rather than degree of
hypercortisolism, and it may also be the case that a linear correla-
tion could not be demonstrated because patients with mild
degrees of cortisol excess were not included in this study. The
terms of the study protocol did not allow for anything more than
the basic screening log details (e.g. patient initials, date examined,
reason for exclusion) to be collected for patients who were
excluded; as such, we are unable to evaluate the effect of including
patients with milder cortisol excess. In addition, the lack of corre-
lation may be linked to differences between patients in their sensi-
tivity to excess cortisol. Further research is required to clarify
these findings and explore the existence of nonlinear relationships.
It is important to consider the patient population enrolled into
this study and the relatively short time period of this analysis
(2 weeks) when interpreting the results. The data presented here
were generated from an analysis of the four baseline 24-h UFC
measurements that were taken from each patient during the
screening period of the largest, prospective, interventional trial of
a medical therapy in patients with Cushing’s disease. Eligibility in
this 12-month, Phase III trial of pasireotide was assessed using the
mean of three or four UFC samples taken within 2 weeks; even
greater variability could be expected over longer time intervals.
Although a UFC level ≥159ULN was required for inclusion into
the study, the overall mean UFC level at entry was approximately
679ULN, and just 7 of 152 patients had individual UFC values
in the normal range. Additional studies are required to show
whether the observed variability would also be applicable in
patients with lower or much higher UFC levels. This is particu-
larly important because this study found that intrapatient vari-
ability in UFC levels increased as UFC levels increased. It is
therefore possible that patients with mild hypercortisolism have
less variability in UFC levels than these patients with moderate-
to-severe hypercortisolism. It is also possible that some of the
observed variability is a reflection of the inherent difficulties with
urine collection and UFC measurement. Although UFC was anal-
ysed at three different central laboratories, they all used the same
assays and adhered to stringent quality control procedures. Fur-
thermore, samples from single patients were all measured in the
same laboratory, so the variability results should not be affected.
However, no cross-validation between the laboratories was per-
formed, which is a potential limitation of the study. Similarly, we
do not believe that the observed variability was influenced by pre-
vious treatment regimens. Although allowed by the inclusion cri-
teria, none of the enrolled patients received prior medical
treatment with long-acting somatostatin analogues. Nineteen
patients had previously been treated with cabergoline at some
time point; however, with a half-life of around 3 days26 and a
protocol-specified washout period of at least 4 weeks, this should
© 2013 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
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not have affected the results. These factors further indicate the
need to study additional parameters, such as late-night salivary
cortisol, to assess their value in the diagnosis and monitoring of
patients with Cushing’s disease.
It would also be interesting to assess the correlation between
UFC values and urinary creatinine levels in patients with Cush-
ing’s disease. It might be expected that 24-h urine creatinine
levels below the lower limit of normal would reflect insufficient
collection, which would in turn affect the accuracy of the UFC
results. However, some patients with Cushing’s disease have
relatively low creatinine levels because of muscle wasting.27
Additional studies are therefore required to assess whether there
is indeed a negative correlation between urinary creatinine and
UFC levels. In addition, because some drugs (fenofibrate and car-
bamazepine) may artificially increase urine cortisol when mea-
sured by HPLC, urine cortisol levels should be interpreted
cautiously in patients receiving these agents.28,29
In conclusion, 24-h UFC measurements in this large cohort
of patients with moderate-to-severe hypercortisolism show high
intrapatient variability. The clinically important results demon-
strate that in these patients, a two-sample UFC measurement
yields a reasonable estimate of intrapatient variation, but that
more precise estimates can be obtained with three or four UFC
measures. Based on these results, we suggest that a minimum of
two samples be obtained for diagnosis, in agreement with the
Endocrine Society’s guidelines,9 as well as for assessing efficacy of
treatment.
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